Examining Changes in Nasal IL-1 During Acute Asthma Exacerbation in Adolescents
| 대상 질환 | Asthma |
|---|---|
| 임상 단계 | 단계 해당 없음 |
| 스폰서 | University of North Carolina, Chapel Hill |
| 상태 | 완료 |
| 참여자 수 | 40 명 |
| 시작일 | 2021년 7월 27일 |
| 완료일 | 2024년 2월 8일 |
| 결과 공개일 | 2026년 6월 29일 |
요약
To study the change from baseline in IL-1β (interleukin 1 beta) concentrations in the nasal airway during acute asthma exacerbation, specifically to measure the degree of change and identify the timing of peak IL-1β concentration. This information will allow the investigators to estimate effect size and guide decisions about the optimal timing of anakinra administration for the future study.
Percentage Change From Baseline in Nasal IL-1β (pg/mL) Concentrations During Asthma Exacerbation
| All Participants | 171.4 percentage change from baseline |
|---|
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- A Study of Remote Asthma Management Using an Integrated Artificial Intelligence-assisted E — Mayo Clinic
- Developing a Childhood Asthma Risk Passive Digital Marker — Indiana University
- A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared With C — Chiesi Farmaceutici S.p.A.
- A Study Evaluating the Efficacy and Safety of Lebrikizumab in Adult Patients With Mild to — Hoffmann-La Roche
- A Study of Lebrikizumab in Participants With Uncontrolled Asthma Who Are on Inhaled Cortic — Hoffmann-La Roche
- Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Sev — AstraZeneca